Elanco Animal Health (NYSE:ELAN) Price Target Cut to $25.00 by Analysts at Morgan Stanley

Elanco Animal Health (NYSE:ELAN) had its price target reduced by equities researchers at Morgan Stanley from $26.00 to $25.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley‘s price target would indicate a potential upside of 8.91% from the stock’s current price.

ELAN has been the subject of a number of other research reports. UBS Group boosted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a report on Friday, October 16th. They issued a “buy” rating and a $32.00 target price for the company. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their target price for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Elanco Animal Health Trading Up 1.3%

Elanco Animal Health stock traded up $0.30 during mid-day trading on Thursday, hitting $22.95. 1,155,747 shares of the company’s stock were exchanged, compared to its average volume of 5,571,732. Elanco Animal Health has a fifty-two week low of $19.40 and a fifty-two week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $11.47 billion, a P/E ratio of -56.07, a PEG ratio of 2.00 and a beta of 1.70. The company’s 50 day simple moving average is $23.16 and its 200-day simple moving average is $23.82.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts anticipate that Elanco Animal Health will post 1.13 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Lawrence Kurzius bought 40,000 shares of Elanco Animal Health stock in a transaction on Thursday, August 20th. The stock was acquired at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy Bettington sold 4,350 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the transaction, the insider directly owned 138,911 shares in the company, valued at $3,194,953. The trade was a 3.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have acquired a total of 63,198 shares of company stock worth $1,473,109 in the last ninety days. 1.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of large investors have recently added to or reduced their stakes in the business. Anchor Investment Management LLC acquired a new stake in Elanco Animal Health in the 2nd quarter valued at about $29,000. Integrated Wealth Concepts LLC bought a new position in Elanco Animal Health in the second quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Elanco Animal Health during the 2nd quarter worth about $38,000. Root Financial Partners LLC acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $41,000. Finally, Bessemer Group Inc. raised its position in shares of Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after acquiring an additional 525 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.